Lundbeck/Takeda Advance Novel Anxiety Candidate To Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Milestone garners Danish firm $40 million four months into collaboration with Takeda.
You may also be interested in...
Lundbeck Looks To Replace Lexapro Earnings Through Ovation Purchase
Acquisition will enhance Lundbeck’s CNS pipeline and add a needed U.S. specialty sales force.
Lundbeck Looks To Replace Lexapro Earnings Through Ovation Purchase
Acquisition will enhance Lundbeck’s CNS pipeline and add a needed U.S. specialty sales force.
Lexapro Pediatric Depression Filing Planned In 2008
Forest and H. Lundbeck announced Phase III study results of the SSRI in adolescents aged 12 to 17.